Vor Biopharma Inc. announced changes to its Board of Directors. Andrew Levin, M.D., Ph.D., resigned from the Board, effective immediately on July 6, 2026. Dr. Levin's resignation was not due to any disagreement with the Company. David Zaccardelli, Pharm.D., was appointed as an independent Class II director on July 7, 2026, filling the vacancy. Dr. Zaccardelli will serve until the Company's 2029 annual meeting of stockholders. He has extensive experience in the pharmaceutical industry, including leadership roles at Verona Pharma plc, Dova Pharmaceuticals, Inc., and Cempra Pharmaceuticals, Inc. Dr. Zaccardelli will receive standard non-employee director compensation, including an annual cash retainer of $40,000. He will also receive an initial stock option grant to purchase up to 68,000 shares or $700,000 in value, and an annual grant of up to 34,000 shares or $350,000 in value. Dr. Zaccardelli will enter into the Company's standard form of indemnification agreement.